Results 41 to 50 of about 18,010 (199)

Genomic and molecular characterisation of a Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam [PDF]

Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +2 more sources

Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study [PDF]

, 2022
Objectives To explore the real-life performance of meropenem/vaborbactam for treating serious KPC-producing Klebsiella pneumoniae infections, including those resistant to ceftazidime/avibactam.
Raffaelli, Francesca, Farese, Alberto, Fabbiani, Massimiliano, Tiseo, Giusy, De Pascale, Gennaro, Viale, Pierluigi, De Rosa, Francesco Giuseppe, Losito, Angela Raffaella, Bassetti, Matteo, Cascio, Antonio, Tumbarello, Mario, Oliva, Alessandra, Montagnani, Francesca, Spanu, Teresa, Morelli, Paola, Pascale, Renato, Venditti, Mario, Del Giacomo, Paola, Falcone, Marco, Giacobbe, Daniele Roberto, Meschiari, Marianna, Vargas, Joel, Signorini, Liana, Mussini, Cristina   +23 more
core   +1 more source

Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections- results from a retrospective multicentre study. [PDF]

Infection
Marino A, Maraolo AE, Mazzitelli M, Oliva A, Geremia N, De Vito A, Gullotta C, Scaglione V, Vania E, Lo Menzo S, Navalesi P, Volpicelli L, Fiori A, Prestifilippo P, Cattelan A, Mastroianni CM, Madeddu G, Cacopardo B, Nunnari G.   +18 more
europepmc   +3 more sources

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales from patients with intra-abdominal infections: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2020

Journal of Microbiology, Immunology and Infection, 2023
Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj   +1 more source

Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy. [PDF]

Antimicrob Agents Chemother
Reed G, Valadez A, Smith BJ, McCreary EK, Kline EG, Neely MN, Squires KM, Shields RK, Rhodes NJ.   +8 more
europepmc   +2 more sources

TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient. [PDF]

J Antimicrob Chemother
Mulé G, Coniglione G, Gatti M, Cona A, Di Martino G, Ranucci G, de Ville de Goyet J, Pea F, Mularoni A.   +8 more
europepmc   +2 more sources

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria

Antibiotics, 2023
Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud, Sandrine Bernabeu, Laurent Dortet   +2 more
doaj   +1 more source

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex

Microbiology Spectrum, 2023
As meropenem-clavulanic acid is recommended for the treatment of drug-resistant tuberculosis, the repurposing of new carbapenem combinations may provide new treatment options, including oral alternatives.
Elin Economou Lundeberg, Viktoria Andersson, Maria Wijkander, Ramona Groenheit, Mikael Mansjö, Jim Werngren, Teresa Cortes, Ivan Barilar, Stefan Niemann, Matthias Merker, Claudio U. Köser, Lina Davies Forsman   +11 more
doaj   +1 more source

In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis

Journal of Antimicrobial Chemotherapy, 2019
Christopher Miller, Bryan T Mogle
exaly   +3 more sources

314. Ceftazidime-Avibactam Versus Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacterales Infections [PDF]

Open Forum Infect Dis
Sara M. Karaba, Dariusz A Hareza, Armani M. Hawes, Yehudit Bergman, Suiyini Fiawoo, Jae Hyoung Lee, Sara E. Cosgrove, Patricia J. Simner, Pranita D. Tamma   +8 more
europepmc   +3 more sources